Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Rivaroxaban Sotorasib Interaction Study
NCT06314763Phase 4Completed
- Sponsor
- Radboud University Medical Center
- Start
- Nov 2023
- Primary completion
- Mar 2024
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, open-label, single-arm trial of sotorasib in non-small cell lung cancer (NSCLC), sponsored by Radboud University Medical Center. Primary endpoints: Area Under the Concentration-Time Curve of Rivaroxaban at Day 16 and Maximum Concentration of Rivaroxaban at Day 16. Started Nov 2023; status: completed.
02
Drugs
sotorasib
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on NCT06314763.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06314763.